Navigation Links
Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis
Date:10/19/2011

PARIS, October 20, 2011 /PRNewswire/ --

- New findings from the pivotal TEMSO Phase III study presented today at the joint ECTRIMS / ACTRIMS Congress -

- U.S. FDA Accepts New Drug Application for Teriflunomide for relapsing forms of MS -

Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today new data from the pivotal TEriflunomide Multiple Sclerosis Oral (TEMSO) Phase III trial showing that once-daily oral teriflunomide significantly reduced annualized rates of relapses leading to hospitalization. New data also confirmed the safety profile and efficacy of teriflunomide over a six-year period after the initial randomization. A total of fifteen presentations on teriflunomide are on the program for the fifth joint triennial congress of the European and American Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS / ACTRIMS) in Amsterdam, Netherlands.

The companies also announced today that the U.S. Food and Drug Administration has accepted for review Sanofi's new drug application (NDA) for oral teriflunomide as a potential therapy for people with relapsing forms of multiple sclerosis (MS).  Sanofi expects to file an application for regulatory approval with the European Medicines Agency (EMA) in the first quarter of 2012.

"The new results of the TEMSO study show that both 7mg and 14mg doses of teriflunomide could reduce the severity of relapses measured through annual rates of relapses leading to hospitalization as well as deliver encouraging long-term results on safety and efficacy," said Professor Paul O'Connor, Director of the MS Clinic at St. Michael's Hospital, Toronto, Canada, and principal investigator of the TEMSO study.

New post-hoc analyses showed that teriflunomide-treated patients' annualize
'/>"/>

SOURCE Sanofi
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Progenitor Cell Therapy, a Wholly-Owned Subsidiary of NeoStem, Inc., Announces Additions to Management
2. NeoStem Acquires Amorcyte, a Clinical Stage Cardiovascular Disease Cell Therapy Company
3. New Findings Reported by TJ Gan and Authors from Duke Anesthesiology Demonstrate Efficacy of Cheetah Medicals NICOM® Bioreactance® Technology to Guide Goal Directed Intraoperative Therapy
4. Antigen Express to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference at the New York Academy of Medicine
5. KGI Professor Awarded Patent for Stem-Cell Therapy Aiding Heart-attack Patients
6. NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011
7. EGEN, Inc. Collaborates With Nanotechnology Characterization Laboratory on Brain Cancer Therapy
8. SanBio Announces Site Opening of Phase 1/2a Clinical Trial of Novel Cell Therapy in Stable Stroke Patients at University of Pittsburgh Medical Center
9. Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy
10. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
11. Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... FRANCISCO , July 30, 2014 ... Congress evaluated the safety and efficacy of CSL ... rejection following kidney transplants in highly sensitized patients. ... inhibitor of the complement system. The ... in significant increases in the levels of complement ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Sales Horizons, ... launch of blended sales training programs for companies engaged ... training programs used by thousands of salespeople over 25 ... sales training program can be customized to address the ... The blended sales training program consists of ...
(Date:7/30/2014)... 2014 Vycom announces the addition of ... to meet Factory Mutual (FM) 4910 fire propagation and ... wet benches, process tools, fume hoods, furniture and cabinetry. ... to semiconductor wafers used in electronic chip manufacturing. ... solution with excellent workability and superior aesthetics. It is ...
(Date:7/30/2014)...   Epic Sciences, Inc. ("Epic"), a private ... personalize and advance the treatment and management of cancer, ... as chairman of Epic,s board of directors. Mr. ... (formerly Invitrogen). Mr. Lucier joins Epic,s board of directors ... cell analysis platform with special focus on the development ...
Breaking Biology Technology:Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3
... Preclinical Research at Upcoming Conferences, CALGARY, Sept. ... ONCY) today announced the participation of five of ... conferences,through November 15, 2008 covering clinical trial results ... time for Oncolytics as we begin to share ...
... Surgeons with No-Touch,Surgical Tool For Precision Brain ... 22 OmniGuide, Inc., announced,today the introduction ... flexible,CO2 laser scalpel for neurosurgery. The BeamPath ... microsurgical tool for various central,nervous system (CNS) ...
... their health, yet up to ... elevated risk for cardiovascular events, yet 20 percent, of those have not spoken ... ... A new survey of men and,women age 40 and older in the United ...
Cached Biology Technology:Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial 2Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial 3OmniGuide Introduces The BeamPath Neuro(TM): A CO2 Laser Fiber for Brain And Spine Surgery 2OmniGuide Introduces The BeamPath Neuro(TM): A CO2 Laser Fiber for Brain And Spine Surgery 3Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 2Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 3Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 4Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 5Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 6Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 7
(Date:7/30/2014)... roughly 3,000 pieces is still in its infant stage. ... be of major significance. "Amazingly often, we are findingin ... amber that we found in Baltic amber," explained Bonn ... amber comes from the Baltic Sea region, which is ... are, e.g., the coastal regions of Mecklenburg, Poland and ...
(Date:7/30/2014)... the first high-resolution map of the carbon stocks ... Per. The new and improved methodology used to ... future market-based carbon economies. The new carbon ... and it provides the critical input to studies ... use, and enforcement purposes. The technique includes the ...
(Date:7/29/2014)... of Bristol,s Nutrition and Behaviour Unit (NBU) has looked ... planning meals. , The research, to be presented at ... (SSIB 2014) in Seattle, USA this week [29 July ... team was led by Professor Jeff Brunstrom, and is ... part of a Biotechnology and Biological Sciences Research Council ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... of branching - wild varieties of the plant Arabidopsis ... of this small mustard plant, a favorite of many ... strains from the polar circle or the subtropics, from ... first time by research teams from Tübingen, Germany, and ...
... discovered one way the p53 gene does what it's known ... in the June 8 issue of Molecular Cell. , ... a microRNA called miR-34a that participates in p53's uncanny ability ... genes in their nuclei. MicroRNAs are small chains of ribonucleic ...
... Aspirin didn’t pan out. Neither did two other potential ... desert shrub is now a front- runner in ongoing ... to inhibit inflammation, cancer and other destructive processes, can ... the annual meeting of the American Aging Association, University ...
Cached Biology News:One species, many genomes 2One species, many genomes 3Common cancer gene sends death order to tiny killer 2Agent slows aging in mice 2
... Concept in Microarrays: Biomedical Photometrics Inc. (Waterloo, ... (Jena, Germany) have collaborated to develop a ... System. The DNAscope AT is based ... DNAscope AT automatically reads up to six ...
... Localization in Early Drug Development with Imaging ... essential drug compound localization data in early ... imaging mass spectrometry service maps unlabeled ... images so you can localize drugs and ...
... provides a comprehensive kinase analysis service ... (PKS) peptide microarrays synthesized on Paraflo ... profiling, quantitative measurement of kinase kinetic ... comprehensive service includes preparation of your ...
Best pricing for 100mg-1.0g scales. Phosphopeptides are our specialty....
Biology Products: